Akums Drugs and Pharmaceuticals · NSE: AKUMS · BSE: 544222
Q3 FY26 results · Oct–Dec 2025
Akums Drugs and Pharmaceuticals reported revenue from operations of ₹1,159.59 crore (up 14.8% from Q3 FY25) and net profit of ₹67.67 crore (up 2.1% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,159.59 | 1,010.41 | +14.8% | 1,017.53 | +14.0% |
| Other income | 34.33 | 14.56 | +135.8% | 32.37 | +6.1% |
| Total income | 1,193.91 | 1,024.97 | +16.5% | 1,049.89 | +13.7% |
| Profit before tax | 99.57 | 91.05 | +9.3% | 65.67 | +51.6% |
| Net profit for the period | 67.67 | 66.31 | +2.1% | 42.70 | +58.5% |
| Attributable to shareholders of the company | 66.32 | 65.18 | +1.7% | 40.78 | +62.6% |
| EPS, basic (₹) | 4.33 | 4.26 | +1.6% | 2.66 | +62.8% |
| Net margin (%) | 5.8 | 6.6 | 4.2 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 368.61 | 337.41 | +9.2% | 309.31 | +19.2% |
| Other income | 29.60 | 33.84 | −12.5% | 27.08 | +9.3% |
| Total income | 398.21 | 371.25 | +7.3% | 336.39 | +18.4% |
| Profit before tax | 35.87 | 54.89 | −34.7% | 31.20 | +15.0% |
| Net profit for the period | 28.11 | 41.17 | −31.7% | 23.46 | +19.8% |
| EPS, basic (₹) | 1.84 | 2.69 | −31.6% | 1.53 | +20.3% |
| Net margin (%) | 7.6 | 12.2 | 7.6 |
Consolidated
- Filed with BSE
- 13 Feb 2026, 16:21 IST
- Board meeting
- 13 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2026, 16:21 IST
- Board meeting
- 13 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE